Single User License
INR 128560
Site License
INR 257120
Corporate User License
INR 385680

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Keratitis-Pipeline Review, H1 2015

Keratitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6626IDB
  • |
  • Pages: 70
  • |
  • April 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Keratitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Keratitis-Pipeline Review, H1 2015', provides an overview of the Keratitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Keratitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Keratitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Keratitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Keratitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Keratitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Keratitis Overview 7

Therapeutics Development 8

Pipeline Products for Keratitis-Overview 8

Pipeline Products for Keratitis-Comparative Analysis 9

Keratitis-Therapeutics under Development by Companies 10

Keratitis-Therapeutics under Investigation by Universities/Institutes 11

Keratitis-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Keratitis-Products under Development by Companies 14

Keratitis-Products under Investigation by Universities/Institutes 15

Keratitis-Companies Involved in Therapeutics Development 16

Adamis Pharmaceuticals Corporation 16

Cellceutix Corporation 17

Dompe Farmaceutici S.p.A. 18

Lee's Pharmaceutical Holdings Limited 19

Peregrine Pharmaceuticals, Inc. 20

RegeneRx Biopharmaceuticals, Inc. 21

Sirnaomics, Inc. 22

The Medicines Company 23

Keratitis-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

brilacidin tetrahydrochloride-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

C-31G-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

dipyridamole-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

IBN-1-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

LQ-7-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

moxifloxacin hydrochloride-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

PGN-632-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

PIM-45-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Recombinant Human Nerve Growth Factor-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

RGN-259-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules to Inhibit ATM for Herpes Keratitis-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

STP-601-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

targocil-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

tigecycline-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Keratitis-Recent Pipeline Updates 51

Keratitis-Dormant Projects 64

Keratitis-Product Development Milestones 65

Featured News & Press Releases 65

Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy 65

Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 66

Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin 66

Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

Number of Products under Development for Keratitis, H1 2015 8

Number of Products under Development for Keratitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Keratitis-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 16

Keratitis-Pipeline by Cellceutix Corporation, H1 2015 17

Keratitis-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 18

Keratitis-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 19

Keratitis-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 20

Keratitis-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 21

Keratitis-Pipeline by Sirnaomics, Inc., H1 2015 22

Keratitis-Pipeline by The Medicines Company, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Keratitis Therapeutics-Recent Pipeline Updates, H1 2015 51

Keratitis-Dormant Projects, H1 2015 64

List of Figures

Number of Products under Development for Keratitis, H1 2015 8

Number of Products under Development for Keratitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 25

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Adamis Pharmaceuticals Corporation

Cellceutix Corporation

Dompe Farmaceutici S.p.A.

Lee's Pharmaceutical Holdings Limited

Peregrine Pharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

Sirnaomics, Inc.

The Medicines Company

Keratitis Therapeutic Products under Development, Key Players in Keratitis Therapeutics, Keratitis Pipeline Overview, Keratitis Pipeline, Keratitis Pipeline Assessment

Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]